Linzagolix
Linzagolix is an oral, non-peptide GnRH antagonist in development for uterine fibroids, endometriosis, and adenomyosis. It potently inhibits gonadotropin release, as demonstrated in clinical and preclinical studies, making it a research tool for investigating hormone-dependent gynecological conditions.
Product Specifications
CAS Number
935283-04-8
Product Name Alternative
Adenomyosis, Gonadotropin releasing hormone receptor, GNRHR, GnRH Receptor, GNRH Receptor, GNRHReceptor, GnRHR, endometriosis, Inhibitor, OBE 2109, OBE2109, OBE-2109, inhibit, KLH 2109, KLH2109, KLH-2109, Linzagolix, uterine fibroids
Field of Research
Pharmacology & Drug Discovery
Purity
99.33% (May vary between batches)
Solubility
DMSO:55 mg/mL (108.18 mM)
Smiles
COc1cc (F) c (cc1OCc1c (OC) ccc (F) c1F) -n1c (=O) [nH]c2csc (C (O) =O) c2c1=O
Molecular Formula
C22H15F3N2O7S
Molecular Weight
508.42
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV782039 1.0 µg DNA
RPS3AP23 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
Sign In for Pricing
View Details 
MBS1208701-01 0.02 mg (E-Coli)
Recombinant Yersinia pseudotuberculosis serotype IB Fatty acid metabolism regulator protein (fadR)
Sign In for Pricing
View Details